Remove 2019 Remove Events Remove Medicine Remove Patients
article thumbnail

2019: A High-storic Year for Nevada NORML Chapters

NORML

Since January, the advocates traveled across Sin City, completed a tour across the Battle Born State and to our nation’s capital on behalf of medical patients and those who have been unfairly affected by the War on Drugs. Initiated a patient voucher program for eligible patients. Established a NORML chapter in Reno.

Advocacy 130
article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

Are you able to answer your patients’ medical marijuana questions? Also, a recent systematic review of healthcare professionals’ “cannabis knowledge” reported “there was a unanimous lack of self-perceived knowledge surrounding all aspects of medicinal cannabis” (2). million medical marijuana patients nationwide.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NORML Chapter Newsletter – May 2019

NORML

NORML Announces Plans for 2019 Conference and Lobby Day. ” Read more from NORML.org ! “Adding a condition for which a physician could recommend medical marijuana instead of an opioid is a safer pain management tool that will be useful for both our doctors and patients.” ” Read more from the Denver Post !

article thumbnail

CBD Enhances Glucose Metabolism via Nuclear Receptors

Project CBD

“Due to its excellent tolerability and promising efficacy … and its innovative new mechanisms of action, we decided to offer a respective treatment with cannabidiol to [the] patient,” they write. Yes, more research is needed — but what matters most to the patient is that it helps. ” Journal of medicinal chemistry vol.

CBD 289
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

article thumbnail

Grassroots Activism and Marijuana Policy: A Winning Combination

NORML

adult-use, patient access, decriminalization etc.) Priority legislation includes: the Ending Federal Marijuana Prohibition Act , the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act , the VA Medicinal Cannabis Research Act and more! Lastly, register for NORML’s 2019 Conference and Lobby Day !

Policy 199
article thumbnail

Answer of the Day for Oct 22, 2021

TheAnswerPage

As suggested by the Australian Centre for Cannabinoid Clinical and Research Excellence, monitoring should initially involve reviewing the patient weekly in person, and via phone if required in the interim between clinical reviews. “A pre-defined measure of success should be negotiated with the patient prior to commencement of therapy.

Therapy 59